ThinkFacility Sign in
  1. Home
  2. News
  3. Business

Demis Hassabis's Isomorphic Labs raises $5 billion to move AI-designed drugs toward trials

The money is meant to carry AI-designed drugs into human trials, but the release gives no date for the first one.

On November 17, 2026, Isomorphic Labs announced a $5 billion Series C round, co-led by Greenoaks and Sequoia Capital. The London company designs medicines with AI, and it put the news out in its own release and on its website.

Andreessen Horowitz joined as a new investor, along with others the company didn't name. Alphabet put in more, and every existing investor took part again, from Thrive Capital to the UK Sovereign AI Fund.

Raised
$5 Billion Series C
Co-led by
Greenoaks and Sequoia Capital
Also in
Andreessen Horowitz (a16z) and Alphabet
Led by
CEO Sir Demis Hassabis and President Max Jaderberg
Offices
London, Cambridge, Massachusetts and Lausanne

What the money's for

Most of it goes into two things. One is IsoDDE, the company's drug design engine, which it describes as a set of simulation models that work across different diseases and different kinds of drug. The other is the plumbing that comes after design: Isomorphic says it's building its own translational and clinical development setup as its candidates head toward trials.

Demis Hassabis, in glasses and a dark jacket, speaks on stage beside a lectern marked EPFL, with a pink and yellow slide behind him
Demis Hassabis speaking at EPFL. Photo: Alain Herzog, CC BY-SA 4.0, via Wikimedia Commons

Hassabis, named in the release as founder and CEO, says the engine is already turning out molecules.

Our drug design engine is generating molecules with unprecedented precision and speed.

From Isomorphic Labs announces $5 Billion Series C funding

The release says that work has produced positive preclinical results, meaning results from the lab before any person takes a drug. Those come from Isomorphic's own programs in oncology and immunology and from work with partners, who aren't named in the release.

Who's paying, and why

The wire listing for the release also shows the round before this one, a $2.1 billion Series B. Add the two and it's $7.1 billion for a company that, by its own account, is still getting ready for clinical entry. Max Jaderberg, its president, says its models produce repeatable advances every week.

Discovering and developing new medicines is an optimization challenge of almost infinite scale

Isomorphic Labs announces $5 Billion Series C funding

That line is from Neil Mehta, who founded Greenoaks. Sequoia's Konstantine Buhler said he's inspired to see the team turn AI into a growing portfolio of drug candidates.

What it means for patients

For anyone waiting on a new cancer or immune treatment, the honest answer is not yet. The release doesn't give a date for a first trial, a drug name or a disease target beyond those two broad areas, and it says only that the preclinical results are setting the stage for clinical entry. Hassabis puts it as driving the first programs toward clinical trials.

Jaderberg's claim is that his teams, machine learning researchers working beside experienced drug hunters, are solving biological problems that stalled traditional research for decades. A trial is where that gets tested, and neither the release nor the company's page says when one starts. I'd watch for the first named candidate.

The money also pays for something less visible: what the company calls the global infrastructure for AI-led bioengineering, and a partner network to study how diseases work at the level of mechanism. Isomorphic didn't put a valuation on the round.

More on Business

All Business stories